Skip to main content

Invitrogen to Sell Genzyme s SAGE Technology

NEW YORK, Oct 10 – Genzyme Moloecular Oncology said Tuesday that Invitrogen had licensed the exclusive rights to sell its Serial Analysis of Gene Expression technology in standardized reagent kits.

Under the terms of the agreement, Genzyme Molecular Oncology of Framingham, Mass., will receive an upfront payment and royalties on the sale of each SAGE kit. The agreement will also enable Invitrogen to distribute Genzyme Molecular Oncology's proprietary bioinformatics software for analysis of SAGE results.

Recently, a public gene expression database repository for SAGE data (SAGEmap) was produced through the US National Institute of Health's Cancer Genome Anatomy Project and is now capable of accepting submissions of SAGE sequence data from any source. The database currently contains over two million SAGE tags.

In addition to the agreement with San Diego-based Invitrogen, Genzyme has signed SAGE agreements with pharmaceutical and biotechnology companies including Celera, Pfizer, Bayer, Novartis Agricultural Discovery Institute, Affymetrix, Curis, Memorec, and Compugen.

All SAGE users are able to access the public database of SAGE information as well as make comparisons with the proprietary SAGE data available on Compugen's LabOnWeb and from Celera.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.